하부요로증상/전립선비대증 일차 치료의 최근 경향
Current Trend of the Primary Treatment in Lower Urinary Tract Symptom / Benign Prostatic Hyperplasia
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Clinical benign prostatic hyperplasia (BPH) is a multifaceted phenomenon that is due to prostatic and bladder influences as well as nonurological causes. It is also important to differentiate between the more common voiding or obstructive symptoms as well as the more bothersome storage or irritative symptoms. Lower urinary tract symptoms (LUTS) and BPH may be two separate conditions with different underlying pathologies. However, they are often treated incorrectly as one entity. Both conditions are very common and they represent chronic conditions of the aging male. They are often associated with a significant reduction in the patients' quality of life. Although these are not new conditions, there have been enormous changes in the methods of assessing and managing the patients with these conditions. This review describes some of the influential studies in this area and the current trends of the primary treatment for LUTS/BPH.
Abstract
Clinical benign prostatic hyperplasia (BPH) is a multifaceted phenomenon that is due to prostatic and bladder influences as well as nonurological causes. It is also important to differentiate between the more common voiding or obstructive symptoms as well as the more bothersome storage or irritative symptoms. Lower urinary tract symptoms (LUTS) and BPH may be two separate conditions with different underlying pathologies. However, they are often treated incorrectly as one entity. Both conditions are very common and they represent chronic conditions of the aging male. They are often associated with a significant reduction in the patients' quality of life. Although these are not new conditions, there have been enormous changes in the methods of assessing and managing the patients with these conditions. This review describes some of the influential studies in this area and the current trends of the primary treatment for LUTS/BPH.
참고문헌 (22)
- Abrams P, "New words for old: lower urinary tract symptoms for “prostatism”", BMJ, 308, pp.929~930 (1994)
- Wein AJ, "Classification of neurogenic voiding dysfunction", J Urol, 125(5), pp.605~609 (1981)
- Abrams P, "Detrusor instability in bladder outlet obstruction", Neurourol Urodyn, 4(4), pp.317~328 (1985)
- Seim A, "The prevalence and correlates of urinary tract symptoms in Norwegian men: the HUNT study", BJU Int, 96(1), pp.88~92 (2005)
- Rosen R, "Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7)", Eur Urol, 44(6), pp.637~649 (2003)
- Parsons JK, "Metabolic factors associated with benign hyperplasia: The Baltimore Longitudinal Study of Aging", J Urol, 175(suppl. 4), pp.432~433 (2006)
- Kaplan SA, "The age related decrease in testosterone is significantly exacerbated in obese men with the metabolic syndrome. What are the implications for the relatively high incidence of erectile dysfunction observed in these men?", J Urol, 176(4 pt 1), pp.1524~1527 (2006)
- Speakman M, "Integrating risk profiles for disease progression in the treatment choice for patients lower urinary tract symptoms", benign prostatic hyperplasia: a combined analysis of external evidence and clinical expertise, 2005, pp.8(4), 369~374
- Emberton M, "Benign prostatic hyperplasia as a progressive disease: a guide to the risk factors and options for medical treatment", Int J Clin Pract, 62(7), pp.1076~1086 (2008)
- Wilt T, "Benign prostatic hyperplasia. Part 2-management", BMJ, 336(7367), pp.206~210 (2008)
- Speakman M, "Lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS", BPH): More than treating symptoms?, 2008, pp.S7, 680~689
- McConnell JD, "The ling-term effect of dexazosin, finasteride and combination therapy on the clinical progression of benign prostatic hyperplasia", N Engl J Med, 349(25), pp.2387~2398 (2003)
- Roehrborn CG, "The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study", J Urol, 179(2), pp.616~621 (2008)
- Barry MJ, "Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign proatatic hyperplasia impact index is perceptible to patients?", J Urol, 154(4), pp.1770~1774 (1995)
- Thompson IM, "Effect of finasteride on the sensitivity of PSA for detecting prostate cancer", J Natl Cancer Inst, 98(16), pp.1128~1133 (2006)
- Redman MW, "Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach", Cancer Prev Res (Phila Pa), 1(3), pp.174~181 (2008)
- MacDiarmid SA, "Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men", Mayo Clin Proc, 83(9), pp.1002~1010 (2008)
- Kaplan SA, "Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: A randomized controlled trial", JAMA, 296(19), pp.2319~2328 (2006)
- Chang DF, "ASCRS White Paper: clinical review of intraoperative floppy-iris syndrome", J Cataract Refract Surg, 34(12), pp.2153~2162 (2008)
- McVary KT, "Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia", J Urol, 177(4), pp.1401~1407 (2007)
- Sauver JL, "NSAIDs may prevent or delay development of BPH in a population- based cohort study", Am J Epidemiol, 164(8), pp.760~768 (2006)
- Colli E, "BXL628, a nevel vitamin D2 analog arrests prostate growth in patients with benign prostatic hyperplasia: a randomized clinical trial", Eur Urol, 49(1), pp.82~86 (2006)